Background Inflammatory bowel diseases [IBD]―ulcerative colitis and Crohn's disease―are
commonly treated with biologic drugs. However, only approximately two-thirds of patients …

Strategies for management of inflammatory bowel diseases are shifting from simple control
of symptoms toward full control of these diseases (clinical and endoscopic remission), with …

Abstract On August 24, 1998, Remicade®(infliximab), the first tumor necrosis factor-α (TNF)
inhibitor, received its initial marketing approval from the US Food and Drug Administration …

Effective prevention and management of osteoporosis would require suitable methods for
population screenings and early diagnosis. Current clinically-available diagnostic methods …

Unambiguous diagnosis of the two main forms of inflammatory bowel diseases (IBD):
Ulcerative colitis (UC) and Crohn's disease (CD), represents a challenge in the early stages …

Inflammatory bowel disease (IBD) has become a major health challenge worldwide.
However, the precise etiological and pathophysiological factors involved in IBD remain …

Objective Accurate differentiation between Crohn's disease (CD) and UC is important to
ensure early and appropriate therapeutic intervention. We sought to identify proteins that …

The protein domain is probably the most ubiquitously affected in disease, response and
recovery, and therefore proteomics holds special promise for biomarker discovery in …

The management of inflammatory bowel disease (IBD) requires a personalized approach to
treat what is a heterogeneous group of patients with inherently variable disease courses. In …

Inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, is a
chronic immune-mediated inflammatory disorder of the gastrointestinal tract that is closely …